A detailed history of Amundi transactions in Regenxbio Inc. stock. As of the latest transaction made, Amundi holds 7,988 shares of RGNX stock, worth $60,868. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,988
Previous 7,988 -0.0%
Holding current value
$60,868
Previous $93,000 10.75%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$11.51 - $21.53 $9,265 - $17,331
805 Added 11.21%
7,988 $93,000
Q1 2024

May 15, 2024

BUY
$12.17 - $24.61 $21,346 - $43,165
1,754 Added 32.31%
7,183 $151,000
Q4 2023

Feb 14, 2024

BUY
$12.89 - $20.82 $6,354 - $10,264
493 Added 9.99%
5,429 $97,000
Q2 2023

Aug 14, 2023

SELL
$17.23 - $21.71 $3,273 - $4,124
-190 Reduced 3.71%
4,936 $98,000
Q1 2023

May 15, 2023

BUY
$18.08 - $24.55 $92,678 - $125,843
5,126 New
5,126 $96,000

Others Institutions Holding RGNX

About REGENXBIO Inc.


  • Ticker RGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,230,000
  • Market Cap $329M
  • Description
  • REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...
More about RGNX
Track This Portfolio

Track Amundi Portfolio

Follow Amundi and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amundi, based on Form 13F filings with the SEC.

News

Stay updated on Amundi with notifications on news.